Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Frequently asked questions
What sector does Tempest Therapeutics Inc (TPST) operate in?
Tempest Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Tempest Therapeutics Inc (TPST) current stock price?
As of the latest data, Tempest Therapeutics Inc stock price is $0.51, with a previous close of $0.51. Tempest Therapeutics Inc lost -$0.00 in the last trading session, representing a -0.47% loss.
What is Tempest Therapeutics Inc (TPST) current market capitalization?
Tempest Therapeutics Inc market cap is approximately 8.44 million.
What is Tempest Therapeutics Inc (TPST) Earnings Per Share (EPS)?
The trailing EPS is -$3.68, and the forward EPS is -$1.21.
What is Tempest Therapeutics Inc (TPST) EBITDA?
Tempest Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.25 million.
Does Tempest Therapeutics Inc (TPST) pay dividends?
No. Tempest Therapeutics Inc does not pay a dividend.
When is Tempest Therapeutics Inc (TPST) next earnings report?
Tempest Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Tempest Therapeutics Inc (TPST) beta (volatility) score?
Tempest Therapeutics Inc has a beta of -1.656, indicating lower volatility than the overall market.
